Format

Send to

Choose Destination
See comment in PubMed Commons below
J Invest Dermatol. 2013 Mar;133(3):595-6. doi: 10.1038/jid.2012.433.

Combination therapy of immunocytokines with ipilimumab: a cure for melanoma?

Author information

1
Tumor Microenvironment and Metastasis Program, Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.

Abstract

Although biological therapy has shown promising clinical responses in many cancers including metastatic melanoma, only a subset of patients has shown marked regression of lesions. In most patients, systemic administration of biological therapies with cytokines is associated with severe toxicities. Schwager et al., in this issue of Journal of Investigative Dermatology, have examined the role of immunocytokines L19-IL2 and L19-TNF to minimize toxicities, and in combination with Ipilimumab they report complete regression of tumors using syngeneic mouse models. The results, if confirmed in clinical trials, will have major implications for the treatment of human cancers, including melanomas.

PMID:
23399823
DOI:
10.1038/jid.2012.433
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center